Informace o publikaci

Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

Autoři	ANTUNES Liliana ROJAS-CASTRO Madelyn LOZANO Marcos MARTINEZ-BAZ Ivan LEROUX-ROELS Isabel BORG Maria-Louise OROSZI Beatrix FITZGERALD Margaret DUERRWALD Ralf JANCORIENE Ligita MACHADO Ausenda PETROVIC Goranka LAZAR Mihaela SOUČKOVÁ Lenka BACCI Sabrina HOWARD Jennifer VERDASCA Nuno BASILE Luca CASTILLA Jesus TERNEST Silke DZIUGYTE Ausra TURI Gergo DUFFY Roisin HACKMANN Carolin KULIESE Monika GOMEZ Veronica MAKARIC Zvjezdana Lovric MARIN Alexandru HUSA Petr NICOLAY Nathalie ROSE Angela M C TEAM VEBIS SARI VE network
Rok publikování	2025
Druh	Článek v odborném periodiku
Časopis / Zdroj	Influenza and Other Respiratory Viruses
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://onlinelibrary.wiley.com/doi/10.1111/irv.70081
Doi	https://doi.org/10.1111/irv.70081
Klíčová slova	case-control study; elderly; severe acute respiratory infections (SARI); test-negative design; vaccine effectiveness
Popis	We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (>= 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.